Cerus PE Ratio 2010-2025 | CERS
Current and historical p/e ratio for Cerus (CERS) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Cerus PE ratio as of June 13, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Cerus PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-06-13 | 1.32 | 0.00 | |
| 2025-03-31 | 1.39 | $-0.10 | 0.00 |
| 2024-12-31 | 1.54 | $-0.11 | 0.00 |
| 2024-09-30 | 1.74 | $-0.11 | 0.00 |
| 2024-06-30 | 1.76 | $-0.13 | 0.00 |
| 2024-03-31 | 1.89 | $-0.17 | 0.00 |
| 2023-12-31 | 2.16 | $-0.21 | 0.00 |
| 2023-09-30 | 1.62 | $-0.28 | 0.00 |
| 2023-06-30 | 2.46 | $-0.29 | 0.00 |
| 2023-03-31 | 2.97 | $-0.27 | 0.00 |
| 2022-12-31 | 3.65 | $-0.25 | 0.00 |
| 2022-09-30 | 3.60 | $-0.22 | 0.00 |
| 2022-06-30 | 5.29 | $-0.24 | 0.00 |
| 2022-03-31 | 5.49 | $-0.28 | 0.00 |
| 2021-12-31 | 6.81 | $-0.31 | 0.00 |
| 2021-09-30 | 6.09 | $-0.35 | 0.00 |
| 2021-06-30 | 5.91 | $-0.36 | 0.00 |
| 2021-03-31 | 6.01 | $-0.36 | 0.00 |
| 2020-12-31 | 6.92 | $-0.36 | 0.00 |
| 2020-09-30 | 6.26 | $-0.39 | 0.00 |
| 2020-06-30 | 6.60 | $-0.44 | 0.00 |
| 2020-03-31 | 4.65 | $-0.48 | 0.00 |
| 2019-12-31 | 4.22 | $-0.52 | 0.00 |
| 2019-09-30 | 5.16 | $-0.52 | 0.00 |
| 2019-06-30 | 5.62 | $-0.50 | 0.00 |
| 2019-03-31 | 6.23 | $-0.47 | 0.00 |
| 2018-12-31 | 5.07 | $-0.44 | 0.00 |
| 2018-09-30 | 7.21 | $-0.42 | 0.00 |
| 2018-06-30 | 6.67 | $-0.43 | 0.00 |
| 2018-03-31 | 5.48 | $-0.49 | 0.00 |
| 2017-12-31 | 3.38 | $-0.56 | 0.00 |
| 2017-09-30 | 2.73 | $-0.59 | 0.00 |
| 2017-06-30 | 2.51 | $-0.61 | 0.00 |
| 2017-03-31 | 4.45 | $-0.63 | 0.00 |
| 2016-12-31 | 4.35 | $-0.62 | 0.00 |
| 2016-09-30 | 6.21 | $-0.64 | 0.00 |
| 2016-06-30 | 6.24 | $-0.67 | 0.00 |
| 2016-03-31 | 5.93 | $-0.66 | 0.00 |
| 2015-12-31 | 6.32 | $-0.66 | 0.00 |
| 2015-09-30 | 4.54 | $-0.76 | 0.00 |
| 2015-06-30 | 5.19 | $-0.74 | 0.00 |
| 2015-03-31 | 4.17 | $-0.73 | 0.00 |
| 2014-12-31 | 6.24 | $-0.68 | 0.00 |
| 2014-09-30 | 4.01 | $-0.53 | 0.00 |
| 2014-06-30 | 4.15 | $-0.67 | 0.00 |
| 2014-03-31 | 4.80 | $-0.60 | 0.00 |
| 2013-12-31 | 6.45 | $-0.65 | 0.00 |
| 2013-09-30 | 6.72 | $-0.62 | 0.00 |
| 2013-06-30 | 4.42 | $-0.41 | 0.00 |
| 2013-03-31 | 4.42 | $-0.42 | 0.00 |
| 2012-12-31 | 3.16 | $-0.42 | 0.00 |
| 2012-09-30 | 3.40 | $-0.51 | 0.00 |
| 2012-06-30 | 3.32 | $-0.38 | 0.00 |
| 2012-03-31 | 4.02 | $-0.41 | 0.00 |
| 2011-12-31 | 2.80 | $-0.35 | 0.00 |
| 2011-09-30 | 2.12 | $-0.25 | 0.00 |
| 2011-06-30 | 3.00 | $-0.40 | 0.00 |
| 2011-03-31 | 2.91 | $-0.41 | 0.00 |
| 2010-12-31 | 2.46 | $-0.43 | 0.00 |
| 2010-09-30 | 3.84 | $-0.50 | 0.00 |
| 2010-06-30 | 3.16 | $-0.56 | 0.00 |
| 2010-03-31 | 2.79 | $-0.61 | 0.00 |
| 2009-12-31 | 1.99 | $-0.71 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.252B | $0.180B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $235.957B | 28.37 |
| Boston Scientific (BSX) | United States | $147.560B | 36.94 |
| Stryker (SYK) | United States | $144.011B | 30.11 |
| EssilorLuxottica (ESLOY) | France | $127.141B | 0.00 |
| Medtronic (MDT) | Ireland | $111.928B | 15.87 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.371B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.926B | 27.87 |
| ResMed (RMD) | United States | $36.560B | 27.46 |
| Agilent Technologies (A) | United States | $33.258B | 21.68 |
| GE HealthCare Technologies (GEHC) | United States | $33.082B | 15.71 |
| Terumo (TRUMY) | Japan | $26.680B | 34.65 |
| Insulet (PODD) | United States | $21.438B | 84.15 |
| Koninklijke Philips (PHG) | Netherlands | $21.384B | 15.37 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.060B | 11.60 |
| Baxter (BAX) | United States | $15.713B | 11.73 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.872B | 0.00 |
| Demant (WILYY) | Denmark | $9.377B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.076B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.175B | 21.49 |
| Lantheus Holdings (LNTH) | United States | $5.385B | 13.58 |
| Prestige Consumer Healthcare (PBH) | United States | $4.149B | 18.54 |
| Perrigo (PRGO) | Ireland | $3.664B | 9.29 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.367B | 15.34 |
| ICU Medical (ICUI) | United States | $3.250B | 23.96 |
| Envista Holdings (NVST) | United States | $3.127B | 25.99 |
| QuidelOrtho (QDEL) | United States | $1.954B | 13.44 |
| LeMaitre Vascular (LMAT) | United States | $1.833B | 40.97 |
| AtriCure (ATRC) | United States | $1.565B | 0.00 |
| Acuren (TIC) | United States | $1.357B | 0.00 |
| Neogen (NEOG) | United States | $1.200B | 15.36 |
| AdaptHealth (AHCO) | United States | $1.161B | 11.78 |
| Green Thumb Industries (GTBIF) | United States | $1.048B | 23.58 |
| BioLife Solutions (BLFS) | United States | $1.046B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.970B | 12.40 |
| Kestra Medical Technologies (KMTS) | United States | $0.904B | 0.00 |
| InMode (INMD) | Israel | $0.844B | 8.51 |
| Evolus (EOLS) | United States | $0.640B | 0.00 |
| CeriBell (CBLL) | United States | $0.624B | 0.00 |
| Owens & Minor (OMI) | United States | $0.602B | 4.99 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.542B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.538B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.524B | 0.00 |
| Valneva SE (VALN) | France | $0.510B | 0.00 |
| Surmodics (SRDX) | United States | $0.417B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.407B | 0.00 |
| SNDL (SNDL) | Canada | $0.339B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.337B | 12.41 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.329B | 58.50 |
| Canopy Growth (CGC) | Canada | $0.272B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.263B | 22.17 |
| Sanara MedTech (SMTI) | United States | $0.256B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.254B | 0.00 |
| ZimVie (ZIMV) | United States | $0.253B | 11.52 |
| Cresco Labs (CRLBF) | United States | $0.245B | 0.00 |
| Quanterix (QTRX) | United States | $0.235B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.221B | 0.00 |
| Biote (BTMD) | United States | $0.207B | 5.82 |
| Brainsway (BWAY) | Israel | $0.206B | 54.50 |
| Omeros (OMER) | United States | $0.199B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.196B | 0.00 |
| Organigram Global (OGI) | Canada | $0.187B | 0.00 |
| High Tide (HITI) | Canada | $0.185B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.179B | 14.59 |
| Verano Holdings (VRNOF) | United States | $0.174B | 0.00 |
| Exagen (XGN) | United States | $0.152B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.140B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.131B | 16.18 |
| Jin Medical (ZJYL) | China | $0.107B | 0.00 |
| MacroGenics (MGNX) | United States | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.64 |
| Veru (VERU) | United States | $0.090B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Agape ATP (ATPC) | $0.084B | 0.00 | |
| TerrAscend (TSNDF) | Canada | $0.075B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Apyx Medical (APYX) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.054B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 55.29 |
| United-Guardian (UG) | United States | $0.037B | 12.90 |
| Rockwell Medical (RMTI) | United States | $0.032B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.019B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| Safety Shot (SHOT) | United States | $0.018B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.012B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| Senestech (SNES) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |